OTSKF News and Press, Otsuka Holdings Co. Ltd. From 07/04/22

The most recent two hottest potatoes in the biotech arena are Aurinia Pharmaceuticals and Seagen. While the latter is mostly/recently associated with an upcoming Merck buyout, the former has been associated with many big pharma names. It's clear (to us) that AUPH should be on the ...

Centessa Pharmaceuticals (NASDAQ:CNTA) stock fell ~11% premarket June 2, after the said it will discontinue developing lixivaptan for a type of kidney disease. The company will discontinue development of lixivaptan for Autosomal Dominant Polycystic Kidney Disease (ADPKD) including both a...

Takeda Pharmaceutical will be able to deliver stellar growth during the next decade. China and emerging markets will be a key driver of growth. The current share price is very undervalued considering the long term growth prospects. For further details see: Takeda Pharmac...

This article has been updated here. For further details see: Akebia Therapeutics plummets 64% on Complete Response Letter for vadadustat

Akebia Therapeutics (AKBA -0.8%) amended a license agreement with Vifor Pharma < > for the former's vadadustat, a potential treatment for anemia due to chronic kidney disease. Under the earlier agreement, Vifor (OTCPK:GNHAF) received an exclusive license to sell vadadustat to Fre...

Aurinia Pharmaceuticals (NASDAQ:AUPH) rose 17% at least partly on some take takeover speculation following comments from Novartis (NYSE:NVS). Novartis reportedly said during its R&D day earlier that it plans to focus on smaller, "bolt-on" deals despite the $20B it will receive f...

Misses on both EPS and revenue estimates in its Q3 earnings report today have led shares of Akebia Therapeutics down (AKBA -9.1%). Year over year, net loss decreased slightly to $59.5M from $60M in the prior-year period. Net revenue for Auryxia (ferric citrate) increased 7% to $36.8M. The com...

Aurinia Pharmaceuticals (NASDAQ:AUPH) fell 1.3% after GlaxoSmithKline (NYSE:GSK) denied a Mail report from Sunday that the company was considering a bid for the company. A GSK spokeswoman told Reuters the report isn't true. Aurinia (AUPH) gained last week after speculation that seve...

Aurinia Pharmaceuticals (NASDAQ:AUPH) may be worth $45-$53/share in a possible sale and may see interest from other pharma cos. besides Bristol Myers, according to Cantor Fitgzerald. Aurinia rose 1.5%. Other companies that could be interested include Amgen (NASDAQ:AMGN), AbbVie (NYSE:ABBV), J...

Aurinia Pharmaceuticals (NASDAQ:AUPH) rose 4.4% after speculation that several other pharma companies may be looking at the company. GlaxoSmithKline (NYSE:GSK), Roche (OTCQX:RHHBY) and Otsuka Pharmaceuticals (OTCPK:OTSKF)  are speculated are speculated to reviewing a poten...